{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:50:43Z","timestamp":1792785043719,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical Scientific Fund of the Mayor of the City of Vienna","award":["23096"],"award-info":[{"award-number":["23096"]}]},{"name":"Hochschuljubil\u00e4umsfonds der Stadt Wien","award":["H-334533\/2021"],"award-info":[{"award-number":["H-334533\/2021"]}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["10.55776\/P35978"],"award-info":[{"award-number":["10.55776\/P35978"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The ongoing evolution of SARS-CoV-2 has generated variants with increased transmissibility and immune evasion, primarily driven by mutations in the receptor-binding domain (RBD). Recent Omicron sublineages, including JN.1, have multiple spike substitutions, including L455S, which is associated with antibody evasion and persists in descendant and currently circulating lineages. While live virus neutralization assays (VNTs) remain the gold standard for evaluating immune responses, their biosafety requirements and technical complexity limit large scale application, prompting an increased reliance on pseudovirus-based systems. In this study, we compared murine leukemia virus (MLV)-based pseudovirus neutralization assays (pVNTs) with VNTs across multiple SARS-CoV-2 variants. We also assessed the contribution of the L455S substitution to immune escape, a mutation consistently implicated as a key determinant of JN.1-associated immune evasion. NT titers obtained with the MLV system showed strong correlation with those of live virus assays, supporting its reliability for variant-specific neutralization studies. Introduction of the L455S mutation into two Omicron variants resulted in substantial reductions in neutralization titers, supporting its immune-evasive properties. Together, these findings validate the MLV-based pseudovirus system as a robust NT surrogate and demonstrate its suitability for evaluating emerging mutations linked to variant evolution, such as the L455S mutation, which played a key role in enabling JN.1 to become dominant.<\/jats:p>","DOI":"10.1038\/s41598-026-53146-7","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:54:15Z","timestamp":1779245655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Validation of an MLV-based SARS-CoV-2 pseudovirus neutralization assay substantiates L455S-mediated antibody escape"],"prefix":"10.1038","volume":"16","author":[{"given":"Dominik","family":"Moll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Springer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Weseslindtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan W.","family":"Aberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith H.","family":"Aberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Medits-Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Stiasny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"53146_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733. https:\/\/doi.org\/10.1056\/NEJMoa2001017 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"53146_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2), e278. https:\/\/doi.org\/10.1016\/j.cell.2020.02.052 (2020).","journal-title":"Cell"},{"key":"53146_CR3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657\u2013663. https:\/\/doi.org\/10.1038\/s41586-021-04385-3 (2022).","journal-title":"Nature"},{"key":"53146_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-022-04411-y","volume":"603","author":"R Viana","year":"2022","unstructured":"Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in Southern Africa. Nature 603, 679\u2013686. https:\/\/doi.org\/10.1038\/s41586-022-04411-y (2022).","journal-title":"Nature"},{"key":"53146_CR5","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adp9279","volume":"9","author":"I Paciello","year":"2024","unstructured":"Paciello, I. et al. SARS-CoV-2 JN.1 variant evasion of IGHV3-53\/3\u201366 B cell germlines. Sci. Immunol. 9, eadp9279. https:\/\/doi.org\/10.1126\/sciimmunol.adp9279 (2024).","journal-title":"Sci. Immunol."},{"key":"53146_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109904","volume":"27","author":"L Zhang","year":"2024","unstructured":"Zhang, L. et al. Rapid spread of the SARS-CoV-2 JN.1 lineage is associated with increased neutralization evasion. iScience 27, 109904. https:\/\/doi.org\/10.1016\/j.isci.2024.109904 (2024).","journal-title":"iScience"},{"key":"53146_CR7","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03503-24","volume":"16","author":"Y Hu","year":"2025","unstructured":"Hu, Y. et al. Comparative analysis of replication and immune evasion among SARS-CoV-2 subvariants BA.2.86, JN.1, KP.2, and KP.3. mBio 16, e0350324. https:\/\/doi.org\/10.1128\/mbio.03503-24 (2025).","journal-title":"mBio"},{"key":"53146_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114520","volume":"43","author":"P Li","year":"2024","unstructured":"Li, P. et al. Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants. Cell. Rep. 43, 114520. https:\/\/doi.org\/10.1016\/j.celrep.2024.114520 (2024).","journal-title":"Cell. Rep."},{"key":"53146_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens14111129","author":"CB Denani","year":"2025","unstructured":"Denani, C. B. et al. Pseudovirus-based neutralization assays as customizable and scalable tools for serological surveillance and immune profiling. Pathogens https:\/\/doi.org\/10.3390\/pathogens14111129 (2025).","journal-title":"Pathogens"},{"key":"53146_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/biom15010135","author":"SN Rizatdinova","year":"2025","unstructured":"Rizatdinova, S. N., Ershova, A. E. & Astrakhantseva, I. V. Pseudotyped viruses: A useful platform for pre-clinical studies conducted in a BSL-2 laboratory setting. Biomolecules https:\/\/doi.org\/10.3390\/biom15010135 (2025).","journal-title":"Biomolecules"},{"key":"53146_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1184362","volume":"14","author":"D Cantoni","year":"2023","unstructured":"Cantoni, D. et al. Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature. Front. Immunol. 14, 1184362. https:\/\/doi.org\/10.3389\/fimmu.2023.1184362 (2023).","journal-title":"Front. Immunol."},{"key":"53146_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.981693","volume":"13","author":"L D'Apice","year":"2022","unstructured":"D\u2019Apice, L. et al. Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay. Front. Immunol. 13, 981693. https:\/\/doi.org\/10.3389\/fimmu.2022.981693 (2022).","journal-title":"Front. Immunol."},{"key":"53146_CR13","doi-asserted-by":"publisher","unstructured":"Grzelak, L. et al. A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. Sci. Transl Med. 12 https:\/\/doi.org\/10.1126\/scitranslmed.abc3103 (2020).","DOI":"10.1126\/scitranslmed.abc3103"},{"key":"53146_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/v12091011","author":"I Hyseni","year":"2020","unstructured":"Hyseni, I. et al. Characterisation of SARS-CoV-2 lentiviral pseudotypes and correlation between pseudotype-based neutralisation assays and live virus-based micro neutralisation assays. Viruses https:\/\/doi.org\/10.3390\/v12091011 (2020).","journal-title":"Viruses"},{"key":"53146_CR15","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.bsheal.2020.08.004","volume":"2","author":"R Yang","year":"2020","unstructured":"Yang, R. et al. Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test in vitro. Biosaf. Health 2, 226\u2013231. https:\/\/doi.org\/10.1016\/j.bsheal.2020.08.004 (2020).","journal-title":"Biosaf. Health"},{"key":"53146_CR16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.gendis.2020.07.006","volume":"7","author":"J Hu","year":"2020","unstructured":"Hu, J. et al. Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2. Genes Dis. 7, 551\u2013557. https:\/\/doi.org\/10.1016\/j.gendis.2020.07.006 (2020).","journal-title":"Genes Dis."},{"key":"53146_CR17","doi-asserted-by":"publisher","unstructured":"Millet, J. K. & Whittaker, G. R. Murine Leukemia Virus (MLV)-based Coronavirus Spike-pseudotyped Particle Production and Infection. Bio Protoc. 6 https:\/\/doi.org\/10.21769\/BioProtoc.2035 (2016).","DOI":"10.21769\/BioProtoc.2035"},{"key":"53146_CR18","doi-asserted-by":"publisher","first-page":"10628","DOI":"10.1128\/JVI.78.19.10628-10635.2004","volume":"78","author":"MJ Moore","year":"2004","unstructured":"Moore, M. J. et al. Retroviruses pseudotyped with the Severe Acute Respiratory Syndrome Coronavirus spike protein efficiently infect cells expressing Angiotensin-converting enzyme 2. J. Virol. 78, 10628\u201310635. https:\/\/doi.org\/10.1128\/JVI.78.19.10628-10635.2004 (2004).","journal-title":"J. Virol."},{"key":"53146_CR19","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/22221751.2020.1743767","volume":"9","author":"J Nie","year":"2020","unstructured":"Nie, J. et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg. Microbes Infect. 9, 680\u2013686. https:\/\/doi.org\/10.1080\/22221751.2020.1743767 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"53146_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12061201","author":"Z Cai","year":"2024","unstructured":"Cai, Z. et al. Validation of a pseudovirus neutralization assay for Severe Acute Respiratory Syndrome Coronavirus 2: A high-throughput method for the evaluation of vaccine immunogenicity. Microorganisms https:\/\/doi.org\/10.3390\/microorganisms12061201 (2024).","journal-title":"Microorganisms"},{"key":"53146_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12030501","author":"Z Cai","year":"2024","unstructured":"Cai, Z. et al. A pseudovirus-based neutralization assay for SARS-CoV-2 variants: A rapid, cost-effective, BSL-2-based high-throughput assay useful for vaccine immunogenicity evaluation. Microorganisms https:\/\/doi.org\/10.3390\/microorganisms12030501 (2024).","journal-title":"Microorganisms"},{"key":"53146_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112824","volume":"28","author":"J Hu","year":"2025","unstructured":"Hu, J. et al. Enhanced reverse zoonotic potential and immune evasion by Omicron JN.1 variant. iScience 28, 112824. https:\/\/doi.org\/10.1016\/j.isci.2025.112824 (2025).","journal-title":"iScience"},{"key":"53146_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01062-20","author":"MC Johnson","year":"2020","unstructured":"Johnson, M. C. et al. Optimized pseudotyping conditions for the SARS-COV-2 spike glycoprotein. J. Virol. https:\/\/doi.org\/10.1128\/JVI.01062-20 (2020).","journal-title":"J. Virol."},{"key":"53146_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.675","volume":"5","author":"Y Lu","year":"2024","unstructured":"Lu, Y., Ao, D., He, X. & Wei, X. The rising SARS-CoV-2 JN.1 variant: Evolution, infectivity, immune escape, and response strategies. MedComm 5, e675. https:\/\/doi.org\/10.1002\/mco2.675 (2024).","journal-title":"MedComm"},{"key":"53146_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adp9279","volume":"9","author":"I Paciello","year":"2024","unstructured":"Paciello, I. et al. SARS-CoV-2 JN.1 variant evasion of IGHV3-53\/3\u201366 B cell germlines. Sci. Immunol. 9, eadp9279. https:\/\/doi.org\/10.1126\/sciimmunol.adp9279 (2024).","journal-title":"Sci. Immunol."},{"key":"53146_CR26","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1016\/S1473-3099(23)00744-2","volume":"24","author":"S Yang","year":"2024","unstructured":"Yang, S. et al. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Lancet Infect. Dis. 24, e70\u2013e72. https:\/\/doi.org\/10.1016\/S1473-3099(23)00744-2 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"53146_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109904","volume":"27","author":"L Zhang","year":"2024","unstructured":"Zhang, L. et al. Rapid spread of the SARS-CoV-2 JN.1 lineage is associated with increased neutralization evasion. iScience 27, 109904. https:\/\/doi.org\/10.1016\/j.isci.2024.109904 (2024).","journal-title":"iScience"},{"key":"53146_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2261566","volume":"12","author":"Z Liang","year":"2023","unstructured":"Liang, Z. et al. Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector. Emerg. Microbes Infect. 12, e2261566. https:\/\/doi.org\/10.1080\/22221751.2023.2261566 (2023).","journal-title":"Emerg. Microbes Infect."},{"key":"53146_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.517","volume":"5","author":"Z Liang","year":"2024","unstructured":"Liang, Z. et al. Development of a SARS-CoV-2 neutralization assay based on a pseudotyped virus using a HIV system. MedComm 5, e517. https:\/\/doi.org\/10.1002\/mco2.517 (2024).","journal-title":"MedComm"},{"key":"53146_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2022.126993","volume":"258","author":"Q Xiang","year":"2022","unstructured":"Xiang, Q., Li, L., Wu, J., Tian, M. & Fu, Y. Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies. Microbiol. Res. 258, 126993. https:\/\/doi.org\/10.1016\/j.micres.2022.126993 (2022).","journal-title":"Microbiol. Res."},{"key":"53146_CR31","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.7150\/ijbs.59184","volume":"17","author":"M Chen","year":"2021","unstructured":"Chen, M. & Zhang, X. E. Construction and applications of SARS-CoV-2 pseudoviruses: A mini review. Int. J. Biol. Sci. 17, 1574\u20131580. https:\/\/doi.org\/10.7150\/ijbs.59184 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"53146_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47393-3","volume":"15","author":"C Liu","year":"2024","unstructured":"Liu, C. et al. Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4\/5 infection. Nat. Commun. 15, 3284. https:\/\/doi.org\/10.1038\/s41467-024-47393-3 (2024).","journal-title":"Nat. Commun."},{"key":"53146_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107028","volume":"143","author":"J Favresse","year":"2024","unstructured":"Favresse, J. et al. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster. Int. J. Infect. Dis. 143, 107028. https:\/\/doi.org\/10.1016\/j.ijid.2024.107028 (2024).","journal-title":"Int. J. Infect. Dis."},{"key":"53146_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70189","volume":"97","author":"J Li","year":"2025","unstructured":"Li, J. et al. Low neutralization of SARS-CoV-2 Omicron BA5248, XBB15 and JN1 by homologous booster and breakthrough infection. J. Med. Virol. 97, e70189. https:\/\/doi.org\/10.1002\/jmv.70189 (2025).","journal-title":"J. Med. Virol."},{"key":"53146_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/v16030473","author":"MS Sohail","year":"2024","unstructured":"Sohail, M. S., Ahmed, S. F., Quadeer, A. A. & McKay, M. R. Cross-reactivity assessment of vaccine-derived SARS-CoV-2 T cell responses against BA.2.86 and JN.1. Viruses https:\/\/doi.org\/10.3390\/v16030473 (2024).","journal-title":"Viruses"},{"key":"53146_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02139-5","volume":"10","author":"J Yang","year":"2025","unstructured":"Yang, J. et al. Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages. Signal Transduct. Target. Ther. 10, 47. https:\/\/doi.org\/10.1038\/s41392-025-02139-5 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"53146_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29801","volume":"96","author":"DN Springer","year":"2024","unstructured":"Springer, D. N. et al. Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection. J. Med. Virol. 96, e29801. https:\/\/doi.org\/10.1002\/jmv.29801 (2024).","journal-title":"J. Med. Virol."},{"key":"53146_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(23)00293-8","volume":"5","author":"DN Springer","year":"2024","unstructured":"Springer, D. N., Medits, I., Weseslindtner, L., Stiasny, K. & Aberle, J. H. SARS-CoV-2 neutralising antibody response to bivalent booster after Omicron infection. Lancet Microbe 5, e8. https:\/\/doi.org\/10.1016\/S2666-5247(23)00293-8 (2024).","journal-title":"Lancet Microbe"},{"key":"53146_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00708-9","volume":"8","author":"DN Springer","year":"2023","unstructured":"Springer, D. N. et al. Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4\/BA.5) increases neutralization of matched Omicron variants. Npj Vaccines 8, 110. https:\/\/doi.org\/10.1038\/s41541-023-00708-9 (2023).","journal-title":"Npj Vaccines"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53146-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53146-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53146-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:10:10Z","timestamp":1784675410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53146-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["53146"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-53146-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"22881"}}